Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/8039| Monoclonal antibody levels and protection from COVID-19 | |
| Eva Maria Stadler Martin Burgess Timothy Schlub Khai Li Chai Zoe McQuilten Erica Wood Mark Polizzotto Stephen Kent Deborah Cromer Miles Davenport David Khoury | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| https://doi.org/10.1101/2022.11.22.22282199 | |
| https://www.medrxiv.org/content/10.1101/2022.11.22.22282199v1 | |
| Abstract Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled trials assessing the use of monoclonal antibodies in preventing symptomatic SARS-CoV-2 infection. We use data on changes in the in vivo concentration of monoclonal antibodies, and the associated protection from COVID-19, over time to model the dose-response relationship of monoclonal antibodies for prophylaxis. We estimate that 50% protection from COVID-19 is achieved with a monoclonal antibody concentration of 939-fold of the in vitro IC50 (95% CI: 135 – 2073). This relationship provides a quantitative tool allowing prediction of the prophylactic efficacy and duration of protection for new monoclonal antibodies administered at different doses and against different SARS-CoV-2 variants. Finally, we compare the relationship between neutralization titer and protection from COVID-19 after either monoclonal antibody treatment or vaccination. We find no evidence for a difference between the 50% protective titer for monoclonal antibodies and vaccination, although vaccination is predicted to be capable of achieving a higher maximum level of protection. | |
| bioRxiv | |
| 28-11-2022 | |
| Preimpreso | |
| Inglés | |
| Público en general | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Materiales de Consulta y Comunicados Técnicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Monoclonal antibody levels and protection from COVID-19.pdf | 2.78 MB | Adobe PDF | Visualizar/Abrir |